Since all phase III studies in primary or recurrent glioblastoma did not find unexpected CNS toxicities or other toxicities when the anti-VEGF-A antibody bevacizumab was combined with chemo-/radiotherapy (Chinot et al. 2014; Gilbert et al. 2014; Wick et al. 2017 [21,22,23]), at least safety and tolerability seem to not be a major issue with these treatment strategies. Here, VEGFA is linked to glioblastoma.